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a b s t r a c t
The immunodominant cryptic epitope SYNTGRFPPL, encoded within open reading frame 2 of the LP-BM5
retroviral gag gene, is critical for protection against retroviral-induced pathogenesis. The goal of this study
was to dissect the memory response against this unique immunodominant cryptic epitope. Unlike the
protective acute effector population of SYNTGRFPPL-speciﬁc CD8 T cells, long-lived SYNTGRFPPL-speciﬁc CD8
T cells lacked the ability to protect susceptible mice infected with LP-BM5 retrovirus. Compared to memory
CD8 T cells against a conventional epitope with similar MHC-I speciﬁcity, primed and restimulated using
similar conditions, long-lived SYNTGRFPPL-speciﬁc CD8 T cells were impaired in their ability to recall against
antigen, with reduced cytolytic capabilities and cytokine production. Since similar priming and restimulation
regimes were utilized to generate each effector CD8 T cell population, this study has potentially broad
implications with regard to the selection criteria of potent, highly conserved cryptic epitopes for use in
epitope-based vaccines.
© 2010 Elsevier Inc. All rights reserved.

Introduction
It is well documented that CD8 T cells signiﬁcantly contribute to
the initial control of HIV-1 infection during the acute phase response
(Borrow et al., 1994, 1997; Koup et al., 1994), although direct
evidence linking superior CD8 T cell immunity with the ability of elite
controllers to effectively suppress virus replication is limited (Bailey
et al., 2009; Deeks and Walker, 2007; Emu et al., 2008). Recently, it has
become apparent that not only the magnitude of the CD8 T cell
response but also the qualitative functions of the effector CD8 T cells
are important for the control of viral load (Almeida et al., 2007;
Critchﬁeld et al., 2008; Ferre et al., 2009). That broad, polyfunctional,
vaccine-induced T cell responses are required for the control of
heterologous SIV challenge in rhesus macaques (Wilson et al., 2009),
and a reduction in the virus set-point of SIV (Liu et al., 2009), indicates
the great therapeutic promise of designing T cell-based vaccines to
control the genetically diverse circulating isolates and escaped
variants of HIV-1 in humans.
Vaccine design has been impeded by the ability of HIV-1 to escape
the immune response due to CD8-driven immune pressure (Borrow
et al., 1997; Goulder et al., 2001, 1997; Price et al., 1997). Immunization
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of rhesus macaques with a mosaic polyvalent vaccine containing the
sequences of multiple in silico recombined gag and nef genes resulted in
increased T cell recognition of a greater breadth of epitopes from each
viral protein and a greater depth of variant sequences of MHC-Irestricted epitopes (Santra et al., 2010). Cryptic epitopes, peptides
generated from non-coding sequences or alternative reading frames
(ARF), establish an extended source of additional immunogenic
peptides for T cell-based vaccines. Immunodominant CD8 T cell
responses directed against a cryptic epitope in SIV were consistently
detected and correlated to effective control of virus replication in MamuB*17+ elite suppressor rhesus macaques (Maness et al., 2007). Natural
in vivo priming against ARF-encoded peptide determinants was also
reported to occur during HIV-1 infection in humans (Cardinaud et al.,
2004). Importantly, the immunodominant cryptic epitopes were highly
conserved among various isolates of the HIV-1 virus, suggesting that
preservation of the protein encoded by the primary reading frame is
necessary for the ﬁtness and survival of the virus (Cardinaud et al.,
2004). Antisense transcripts were also shown to contribute signiﬁcantly
to the pool of immunogenic cryptic epitopes driving virus escape or
reversion in a large cohort of South Africans with chronic HIV-1 infection
(Bansal et al., 2010), demonstrating the large repertoire of unconventional immunodominant antigens available for vaccines.
Previously, our laboratory has deﬁned a CD8 CTL major, immunodominant, cryptic epitope in a murine model of retrovirus-induced
immunodeﬁciency, namely LP-BM5, which causes a pathology in mice
similar to AIDS in humans, termed murine AIDS (MAIDS) (Mayrand
et al., 2000, 1998; Schwarz and Green, 1994). The LP-BM5 cryptic
epitope, SYNTGRFPPL, is encoded within an ARF, open reading frame
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(ORF) 2, of the retroviral gag gene (Mayrand et al., 1998) and was, to our
knowledge, the ﬁrst described ARF epitope in a retroviral system and
only the second naturally occurring ARF epitope in any system, the ﬁrst
being in melanomas (Wang et al., 1996; Wang and Rosenberg, 1996).
After extensive sequence analysis of the LP-BM5 genome for conventional MHC class I-restricted epitopes, we demonstrated that
SYNTGRFPPL was the protective epitope recognized by CD8 T cells
during LP-BM5 infection in resistant BALB/c mice (Mayrand et al., 1998;
Schwarz and Green, 1994). Using this murine model of retroviral
immunodeﬁciency, our laboratory was the ﬁrst to establish that CD8 T
cells recognizing cryptic epitopes were necessary and sufﬁcient for
protection against retroviral pathogenesis: adoptive transfer of
SYNTGRFPPL-speciﬁc effector CD8 T cells resulted in dramatic, if not
complete, protection from disease and viral load when used to
reconstitute MAIDS-susceptible CD8−/− BALB/c mice (Ho and Green,
2006b). Due to the similarities between HIV in humans and the disease
manifestations of LP-BM5 infection in susceptible mice (Jolicoeur, 1991;
Liang et al., 1996; Morse et al., 1992), the MAIDS model of retroviral
infection represents an opportunity to study in detail the speciﬁc CD8 T
cell response, including the memory phase, against cryptic/ARF epitopes
encoded by an immunodeﬁciency causing retrovirus.
The goal of this study was to utilize this unique CTL response to
dissect the memory response against an immunodominant cryptic
epitope. Here we demonstrate that CD8 T cells recognizing SYNTGRFPPL
become phenotypically and functionally distinct over time, compared to
CD8 T cells recognizing non-LP-BM5-associated epitopes with similar
MHC-I speciﬁcity. Speciﬁcally, Kd/SYNTGRFPPL-speciﬁc CD8 T cells are
long lived, have a central memory phenotype, but have a reduced
capacity to recall against antigen, as evidenced by a lack of effector
cytokines IFNγ, TNFα, and IL-2, and cytolytic capabilities, i.e., these longlived CD8 T cells exhibit a memory response of poor quality. Although Kd/
SYNTGRFPPL-speciﬁc CD8 T cells have long-term, antigen-independent
persistence when transferred into CD8−/− recipients or congenic
recipients with intact CD8 compartments, they fundamentally lack the
ability to protect CD8−/− mice infected with LP-BM5 retrovirus, despite
their ability to confer protection as acute effector CD8 T cells.
Results
Characterization of the Kd/SYNTGRFPPL-speciﬁc CD8 T cell response
during protection of BALB/c mice infected with LP-BM5 retrovirus
Acute protection of MAIDS-resistant BALB/c mice infected with
murine retrovirus LP-BM5 appears to be solely due to a CD8 T cell
response against a single H-2K d -restricted cryptic epitope,
SYNTGRFPPL, located within open reading frame 2 of the retroviral
gag gene (Mayrand et al., 2000, 1998; Schwarz and Green, 1994). Even
at high virus doses (2 × 105 pfu, compared to the normal dose of
5 × 104 pfu), LP-BM5-infected BALB/c mice failed to develop disease
manifestations typical of murine AIDS (MAIDS), such as severe
lymphadenopathy and immunosuppression, measured by spleen
weight and lymphocyte responsiveness to mitogens, respectively,
measured here at 11 weeks-post infection (Fig. 1A). Although Kd/
SYNTGRFPPL-speciﬁc CD8 T cells were not readily detectable ex vivo
by tetramer staining at early temporal points during infection (data
not shown), compared to naive CD8 T cells, SYNTGRFPPL-speciﬁc
secretion of IFNγ (Fig. 1B), and in vivo lysis of SYNTGRFPPL-pulsed
syngeneic target cells, indicated the peak effector response occurred
at approximately 10 days post-infection with LP-BM5 (Fig. 1C). This
effector CD8 T cell response preceded maximum virus levels, which
peaked around day 12 (Fig. 1D). Following expansion of effector CD8 T
cells, viral load rapidly declined, so that by days 20–30 of infection,
retroviral levels were not readily detected above background
(Fig. 1D). As antigen levels diminished, a rapid contraction of the
functional CD8 T cell response was observed by 15 days post-infection
(Fig. 1B–C).
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Characterization of the Kd/SYNTGRFPPL-speciﬁc memory CD8 T cell
response during protection of susceptible BALB/c CD8−/− mice
infected with LP-BM5 retrovirus
Due to the limitations of easily detecting Kd/SYNTGRFPPL-speciﬁc
tetramer+ CD8 T cells during infection of BALB/c mice with LP-BM5 and
in order to investigate the quality of the memory response to
SYNTGRFPPL, we utilized an adoptive transfer approach previously
developed by our laboratory to confer protection in susceptible BALB/c
CD8−/− mice infected with LP-BM5 (Ho and Green, 2006b). These
results, coupled with our earlier work, indicated that BALB/c mice are
resistant to LP-BM5 pathogenesis due to a protective CD8 T cell response
directed against the cryptic epitope SYNTGRFPPL (Mayrand et al., 2000,
1998; Schwarz and Green, 1994). Thus, this adoptive transfer approach
adequately recapitulated the CD8-mediated protection observed in
intact BALB/c mice, presenting a unique opportunity to study this
protective CD8 T cell response in detail.
Acute effector CD8 T cells were generated by priming BALB/c mice
with Vac-DG, a recombinant vaccinia virus with the gag gene of the LPBM5 retrovirus inserted (Schwarz and Green, 1994). Three weeks postpriming, splenocytes were harvested from the primed BALB/c mice, and
Kd/SYNTGRFPPL-speciﬁc effector CD8 T cells were cultured in vitro for
9 days with synthetic SYNTGRFPPL peptide and low dose IL-2. Prior to
transfer into CD8−/− mice, as we have previously published (Ho and
Green, 2006b), the Kd/SYNTGRFPPL-speciﬁc effector population consisted of approximately 30% CD8 T cells speciﬁc for SYNTGRFPPL based
upon tetramer staining and functional analysis. CTL function was robust:
antigen-speciﬁc lysis of chromium-labeled target cells pulsed with
SYNTGRFPPL peptide was signiﬁcantly greater than lysis of target cells
pulsed with irrelevant GFNKLRSTL peptide (P b 0.01) (Supplementary
Fig. 1A). Substantial SYNTGRFPPL-speciﬁc co-production of IFNγ and
TNFα was also observed after in vitro restimulation with SYNTGRFPPL
peptide (36.2% versus 3.3% when restimulated with irrelevant
GFNKLRSTL peptide), along with a minor population of CD8 T cells
producing IFNγ and TNFα and co-producing IL-2 after restimulation
with SYNTGRFPPL peptide (0.99% versus 0% when restimulated with
irrelevant GFNKLRSTL peptide) (Supplementary Fig. 1B). Based on
tetramer analysis of the effector CD8 T cells, expression of CD62L and
CD127 (IL-7Rα) were roughly similar to the expression of naive CD8 T
cells (Supplementary Fig. 1C), while surface expression of the activated
isoform of CD43 (1B11), CD44, and CD122 (IL-2Rβ) were all high,
compared to naive CD8 T cells.
Eleven weeks post-transfer of the acute Kd/SYNTGRFPPL-speciﬁc
effector CD8 T cells into CD8−/− mice, we were able to detect equivalent
percentages and numbers of long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T
cells by tetramer analysis of lymphocytes isolated from the spleens of
both LP-BM5-infected and non-infected CD8−/− recipient mice
(Fig. 2A), indicating that maintenance of the transferred CD8 T cells
was antigen-independent. Phenotypically, when the CD62L and CD122
expression was compared between long-lived and acute effector Kd/
SYNTGRFPPL-speciﬁc CD8 T cells, there was roughly similar expression
by each antigen-speciﬁc population. In particular, when the MFI of
CD122 and CD62L were normalized to the expression on naive control
CD8 T cells, long-lived and acute effector Kd/SYNTGRFPPL-speciﬁc CD8 T
cells had a comparatively similar fold-change in expression of these two
proteins (Fig. 2B, Supplementary Fig. 2). However, compared to acute
effector CTL, the expression of CD127 and CD44 on long-lived memory
Kd/SYNTGRFPPL-speciﬁc CD8 T cells showed a trend towards being
approximately 50–60% higher when normalized to the expression on
naive CD8 T cells, although the increases in CD127 and CD44 levels were
not statistically signiﬁcant compared to the expression on acute effector
CTL (Supplementary Fig. 2).
Unlike acute SYNTGRFPPL-speciﬁc effector CD8 T cells, functional
defects were observed in the long-lived SYNTGRFPPL-speciﬁc CD8 T cell
population after restimulation with SYNTGRFPPL peptide, as there were
minimal, if any, cells within the transferred population able to produce
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Fig. 1. Characterization of the Kd/SYNTGRFPPL-speciﬁc effector and memory CD8 T cell response during LP-BM5 infection of BALB/c mice. (A) BALB/c mice were infected with 1 or
2 × 105 pfu of LP-BM5 retrovirus for 11 weeks, after which disease was assessed. The bottom panel, spleen weight; top panel, B and T cell responsiveness to mitogen stimulation with
LPS and ConA, respectively. The data are represented as the percentage counts per minute (CPM) relative to the appropriate non-infected control. (B–C) Functional characterization
of the Kd/SYNTGRFPPL-speciﬁc CD8 T cell response during LP-BM5 infection in BALB/c mice. (B) ELISPOT analysis of IFNγ production by effector and memory CTL. Splenocytes were
isolated from BALB/c mice infected for 5, 10, 15, or 50 days with LP-BM5 retrovirus and stimulated ex vivo for 72 h with SYNTGRFPPL peptide. *P b 0.05. (C) In vivo cytolysis of
SYNTGRFPPL-pulsed syngeneic target splenocytes in BALB/c mice infected with LP-BM5 for 5, 10, 15, or 50 days at the time of target cell injection. Signiﬁcance is in comparison to
control naive BALB/c mice. *P b 0.05. (D) Viral RNA expression of BM5def from spleen-derived RNA samples isolated from LP-BM5-infected BALB/c mice at the indicated temporal
points. Expression levels of BM5def are relative to the cycle threshold values obtained for β-actin controls.

effector cytokines IFNγ and TNFα during an antigen-speciﬁc recall
response, compared to the higher proportion (28%) of the acute effector
CTL population able to produce TNFα (Fig. 2C). When stimulated with
ConA, approximately 35–40% of the remaining transferred CD8 T cells
were able to produce TNFα and/or IFNγ (Fig. 2C). These results indicated
that, although long-lived SYNTGRFPPL-speciﬁc CD8 T cells had
phenotypic attributes similar to canonical central memory T cells as
described in the literature (Wherry et al., 2003) (CD44high and

CD62Lmoderate/high), they appeared to have functional deﬁciencies
when restimulated with peptide ex vivo.
Impaired recall capacity and memory responsiveness are unique to
long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T cells
To conﬁrm whether the long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T
cells had severely diminished function and to demonstrate that any

Fig. 2. Eleven weeks post-transfer into CD8−/− recipient mice, Kd/SYNTGRFPPL-speciﬁc CD8 T cells are long-lived and are unable to produce cytokines in response to peptide
restimulation. (A) Percentages and total numbers of Kd/SYNTGRFPPL-speciﬁc CD8 T cells remaining 11 weeks post-transfer into either naive or LP-BM5-infected CD8−/− recipient
mice. Plots are gated on total CD8+ lymphocytes. Numbers in upper right quadrants indicate percent of tetramer-positive Kd/SYNTGRFPPL-speciﬁc CD8 T cells. In the right-hand
panel, total numbers of tetramer-positive Kd/SYNTGRFPPL-speciﬁc CD8 T cells are calculated, based upon total splenic leukocytes. (B) Surface staining of CD62L, CD44, CD122, and
CD127 expression on Kd/SYNTGRFPPL-speciﬁc CD8+ splenocytes isolated either 1 week post-transfer into non-infected CD8−/− recipients (to characterize naive versus acute
effector CD8+ splenocytes at an early effector stage) or 11 weeks post-transfer (to characterize naive versus long-lived SYNTGRFPPL-speciﬁc CD8+ splenocytes at a memory stage).
Plots are gated on CD8+ cells. Numbers in the upper quadrants represent the percentage of total CD8+ T cells staining for each marker. Numbers in parentheses indicate the MFI ±
standard deviation for each protein expressed on total CD8+ tetramer-speciﬁc T cells; for the naive controls, MFI is calculated based on total CD8+ T cells. (C) Antigen-speciﬁc IFNγ
and TNFα cytokine production after stimulation for 24 h ex vivo with synthetic peptide. Plots represent intracellular staining of naive, acute effector, or long-lived CD8+ T cells
stimulated ex vivo for 24 h with synthetic SYNTGRFPPL peptide + IL-2 or irrelevant GFNKLRSTL peptide + IL-2. Stimulation with ConA was used as a positive indicator of IFNγ and
TNFα cytokine production. Plots are gated on CD8+ cells. Numbers in quadrants represent percentage of total CD8+ T cells staining positive for each cytokine. Data are representative
of at least 2 experiments with 4–6 animals per group.
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differences in function were not simply due to the adoptive transfer
system, we compared effector function of transferred Kd/SYNTGRFPPL
versus Kd-restricted gammaherpesvirus-speciﬁc, long-lived effectors,
the latter of which were elicited with an identical stimulation
protocol. Thus, BALB/c mice were primed with either Vac-DG or
Vac-M2, a recombinant vaccinia virus containing the latent gammaherpesvirus gene, for 3 weeks followed by further in vitro expansion
with either synthetic peptide SYNTGRFPPL or GFNKLRSTL, the
immunodominant H-2Kd-restricted gammaherpesvirus latent peptide, for 9 days. Following culture, CD8−/− recipient mice were
reconstituted with equal ratios of effector CD8 T cells speciﬁc for each
epitope, SYNTGRFPPL and GFNKLRSTL, based upon tetramer analysis.
Prior to transfer of these two acute effector populations, clear
functional and phenotypic differences between each population were
observed. As expected, after 9 days of in vitro restimulation with
GFNKLRSTL peptide, acute Kd/GFNKLRSTL-speciﬁc effector CD8 T cells
had a classic effector phenotype in which a majority (N60%) of
antigen-speciﬁc CD8 T cells were CD62Llow and essentially all
tetramer+ cells were CD44high (Fig. 3A). However, although analogously generated Kd/SYNTGRFPPL-speciﬁc acute effector CD8 T cells
were capable of antigen-speciﬁc lysis and cytokine production (Fig.
3B–C), they retained signiﬁcantly higher expression levels of CD62L
(P b 0.05) compared to GFNKLRSTL-primed CTL, a phenotype similar
to either naive or resting central memory CD8 T cells (Fig. 3A,
Supplementary Fig. 1C). Reﬂective of this phenotypic difference in
CD62L expression between the two effector populations, cytokine
production also differed. Co-production of the effector cytokines IFNγ
and TNFα by GFNKLRSTL-primed effector CD8 T cells was observed only
in the CD62Llow population (Fig. 3B) after restimulation with
GFNKLRSTL peptide, phenotypically characteristic of effector CD8 T
cells. In sharp contrast, it was the large proportion of CD62Lmoderate/high
SYNTGRFPPL-primed CD8 T cells that produced both IFNγ and TNFα in
response to homologous peptide restimulation (Fig. 3B). There were
essentially no cells producing effector cytokines within the CD62Llow
population of SYNTGRFPPL-primed CD8 T cells after restimulation with
SYNTGRFPPL.
Although these two acute effector populations had differing
expression patterns of CD62L with correspondingly differing production
of effector cytokines between the CD62Llow vs. CD62Lmoderate/high
populations, they exhibited equivalent in vitro cytolysis of relevant
antigen-pulsed target cells (Fig. 3C). The ability of acute Kd/SYNTGRFPPLspeciﬁc effector CD8 T cells to lyse SYNTGRFPPL-pulsed target cells was
expected, as it has been previously reported that they protect susceptible
CD8−/− mice infected with the LP-BM5 retrovirus through a perforinmediated mechanism (Rutkowski et al., 2009). Collectively, these data
indicate that the unique effector phenotype of acute Kd/SYNTGRFPPLspeciﬁc effector CD8 T cells is not a result of our experimental system of in
vitro restimulation, as acute Kd/GFNKLRSTL-speciﬁc effector CD8 T cells,
which were generated under identical conditions, are phenotypically and
functionally similar to classic acute effector CD8 T cells.
Equal numbers of such acute Kd/SYNTGRFPPL-speciﬁc and Kd/
GFNKLRSTL-speciﬁc effector CD8 T cells were then transferred either
into individual CD8−/− recipient mice, or at a 1:1 ratio in the same
CD8−/− recipient mouse. Eleven weeks post-transfer, the ability of
each long-lived effector population to recall was compared by
measuring ex vivo cytokine production and in vivo antigen-speciﬁc
lysis. Approximately equivalent numbers of each effector population
were detectable by tetramer analysis at this temporal point (data not

shown), to eliminate the possibility that any observed differences in
function were due to the transfer or survival of greater numbers of
tetramer-speciﬁc T cells in either population.
It was possible that, in comparison to the immunodominant
vaccinia-speciﬁc memory effector population also present within mice
receiving acute Kd/SYNTGRFPPL-speciﬁc effector CD8 T cells, the lack of
full function in the long-lived Kd/SYNTGRFPPL-speciﬁc population was
due to a proportionately minimal acute lytic response. If this were the
case, after the contraction phase, detection of memory ex vivo would be
difﬁcult without expansion of long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T
cells in vitro. To test this, BALB/c mice were primed with Vac-DG, and
after 5 days, splenic CD8 T cells from the primed mice were isolated and
used to reconstitute CD8−/− mice. After a 3-day rest period, recipient
mice were injected with a 1:1 ratio of CFSE-labeled syngenic target cells
pulsed with SYNTGRFPPL- or the Vac Kd-presented epitope, KYGRLFNEI,
to monitor the in vivo cytolytic capabilities of the corresponding two
speciﬁc CD8 T cell effector populations. After 16 h, compared to nonpulsed control targets, lysis of each target population was roughly
equivalent, demonstrating that as acute effectors, both Kd/SYNTGRFPPLspeciﬁc and Kd/KYGRLFNEI-speciﬁc CD8 T cells were able to lyse
relevant peptide-pulsed target cells 7–8 days post-priming in vivo
(Fig. 4A). Thus, the altered cell-surface phenotype and diminished
cytokine production of long-lived SYNTGRFPPL-speciﬁc CD8 T cells are
more than likely not a result of a proportionately diminished initial
acute effector response, at least in terms of cytolytic capabilities.
In the CD8−/− recipients receiving equivalent numbers of each acute
effector population (detected by tetramer staining), signiﬁcantly greater
percentages of CD8 T cells were able to co-produce effector cytokines
IFNγ and TNFα after restimulation with GFNKLRSTL peptide compared to
CD8 T cells recalled with SYNTGRFPPL peptide (8.05% versus 2.49%,
P b 0.01) (Fig. 4B). The relative inability of CD8 T cells to produce effector
cytokines in response to SYNTGRFPPL restimulation ex vivo was also
observed in CD8−/− recipient mice receiving only acute Kd/SYNTGRFPPLspeciﬁc effector CD8 T cells compared to the cytokine response of the
same T cells after restimulation with irrelevant GFNKLRSTL peptide
(1.74% versus 2.96%) (Fig. 4B). Conversely, GFNKLRSTL-speciﬁc cytokine
production observed from CD8 T cells isolated from CD8−/− mice
receiving only acute Kd/GFNKLRSTL-speciﬁc effector CD8 T cells was
signiﬁcantly greater compared to cytokine production of the same group
of T cells restimulated with irrelevant SYNTGRFPPL peptide (5.49% versus
1.42%, P b 0.01) (Fig. 4B). Thus, the defect in cytokine production of longlived Kd/SYNTGRFPPL-speciﬁc CD8 T cells collected from mice receiving
equivalent numbers of each effector population 11 weeks prior was not
due to a competitive/ﬁtness advantage that the Kd/GFNKLRSTL-speciﬁc
population may have had over Kd/SYNTGRFPPL-speciﬁc CD8 T cells after
transfer into the same host.
Since, in each epitope-speciﬁc system, CD8−/− mice received a
heterogeneous population of CD8 T cells that were generated through
initial priming with analogous vaccinia virus vectors, we also
compared the ability of vaccinia-speciﬁc CD8 T cells collected from
mice receiving acute Kd/SYNTGRFPPL- or Kd/GFNKLRSTL-speciﬁc CD8
T cells, or in mice administered equal proportions of acute Kd/
SYNTGRFPPL- and Kd/GFNKLRSTL -speciﬁc CD8 T cells, to recall upon
stimulation with one of the immunodominant H-2Kd vaccinia
epitopes, KYGRLFNEI (Oseroff et al., 2008; Tscharke et al., 2006).
Compared to the proportions of CD8 T cells co-producing IFNγ and
TNFα when restimulated with irrelevant SYNTGRFPPL peptide, there
was a slightly greater (although not signiﬁcant) proportion of CD8 T

Fig. 3. Acute effector Kd/SYNTGRFPPL ORF2-speciﬁc CD8 T cells have a unique phenotype but similar functional capabilities compared to acute effector CD8 T cells recognizing a
conventional antigen after priming and stimulation under similar conditions. Effector CTLs were derived from BALB/c mice primed for 3 weeks with either Vac-DG or Vac-M2,
followed by in vitro stimulation for an additional 9 days with SYNTGRFPPL or GFNKLRSTL peptide, respectively. (A) Phenotypic comparison of CD62L and CD44 surface staining on
effector Kd/SYNTGRFPPL- or Kd/GFNKLRSTL-speciﬁc CD8 T cells. Plots represent gating on tetramer-speciﬁc CD8+ cells. The bottom panels represent the MFI for CD44 and CD62L
expression on Kd/SYNTGRFPPL- or Kd/GFNKLRSTL tetramer-speciﬁc CD8 T cells. (B) Intracellular expression of IFNγ and TNFα by CD62Llow and CD62Lhigh effector CD8+ T cells
stimulated with SYNTGRFPPL or GFNKLRSTL peptides. Intracellular plots are gated on CD62Lhigh or CD62Llow CD8+ lymphocytes. (C) Peptide-speciﬁc lysis of SYNTGRFPPL- or
GFNKLRSTL-pulsed target cells labeled with 51Cr by Kd/SYNTGRFPPL- or Kd/GFNKLRSTL-speciﬁc CD8 T cells.
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cells co-producing IFNγ and TNFα after stimulation ex vivo with
KYGRLFNEI peptide in mice receiving adoptive transfer of acute Kd/
SYNTGRFPPL-speciﬁc CD8 T cells (4.73% versus 1.74%) (Fig. 4B). In
CD8−/− mice receiving acute Kd/GFNKLRSTL-speciﬁc CD8 T cells,
there was a slightly lower percentage of CD8 T cells co-producing IFNγ
and TNFα upon restimulation with KYGRLFNEI peptide compared to
GFNKLRSTL-responsive T cells (2.26% versus 5.49%) (Fig. 4B). However, the percentage of CD8 T cells identiﬁed from recipient mice
receiving equivalent numbers of both acute Kd/GFNKLRSTL- and Kd/
SYNTGRFPPL-speciﬁc CD8 T cells that co-produced IFNγ and TNFα
when stimulated with KYGRLFNEI was signiﬁcantly greater than the
proportion of CD8 T cells co-producing effector cytokines IFNγ and
TNFα upon restimulation with SYNTGRFPPL peptide (5.11% versus
2.49%, P b 0.01) (Fig. 4B). Collectively, these results indicated that Kd/
KYGRLFNEI- and Kd/GFNKLRSTL-speciﬁc CD8 T cell memory cytokine
responses raised in parallel to H-2Kd-restricted epitopes are of a
qualitatively greater magnitude than the memory cytokine response
to the cryptic epitope SYNTGRFPPL.
Acute Kd/SYNTGRFPPL-speciﬁc effector CD8 T cells utilize perforinmediated cytolysis of LP-BM5-infected cells as the preferential effector
mechanism during protection of LP-BM5-infected CD8−/− mice, as
previously reported (Rutkowski et al., 2009). Therefore, the in vivo
cytolytic ability of memory CD8 T cells during recall in this co-adoptive
transfer model was tested. We measured lysis by immunizing CD8−/−
recipient mice that were previously reconstituted with either acute Kd/
SYNTGRFPPL-speciﬁc or Kd/GFNKLRSTL-speciﬁc effector CD8 T cells,
followed by administration of either Vac-DG or Vac-M2, to boost the
long-lived Kd/SYNTGRFPPL-speciﬁc or Kd/GFNKLRSTL-speciﬁc memory
CD8 T cells, respectively. Boosting was followed by challenge with two
target cell types delivered, in each case, to individual recipient mice:
either a 1:1 ratio of SYNTGRFPPL- and KYGRLFNEI-, or GFNKLRSTL- and
KYGRLFNEI-, pulsed ﬂuorescently labeled syngeneic targets to mice
reconstituted with acute Kd/SYNTGRFPPL-speciﬁc or Kd/GFNKLRSTLspeciﬁc effector CD8 T cells, respectively. After boosting with Vac-DG or
Vac-M2 in recipients initially receiving single populations of either acute
Kd/SYNTGRFPPL- or Kd/GFNKLRSTL-speciﬁc effector CD8 T cells (i.e.
11 weeks prior), signiﬁcantly greater lysis of both GFNKLRSTL- and
KYGRLFNEI-pulsed targets was observed, compared to the lysis of
SYNTGRFPPL-pulsed targets (P b 0.05 and P b 0.01, respectively) (Fig. 4C,
left panel). Defective lysis of SYNTGRFPPL-pulsed targets was also
observed after boosting with vaccinia vectors in recipients receiving a
1:1 ratio of each acute effector population (Fig. 4C, right panel). The
recall response of long-lived Kd/GFNKLRSTL-speciﬁc CD8 T cells after
boosting withVac-M2 was signiﬁcantly greater than the primary
response, prior to boosting with Vac-M2, both in recipients receiving
single populations of CD8 T cells, or in recipients receiving a 1:1 ratio of
acute Kd/SYNTGRFPPL- and Kd/GFNKLRSTL-speciﬁc effector CD8 T cells
(P b 0.05) (Fig. 4C). Conversely, lysis of SYNTGRFPPL-pulsed target cells
was undetectable/low and essentially unchanged after Vac-DG recall
(Fig. 4C). The near inability of Vac-DG-recalled SYNTGRFPPL-speciﬁc
memory cells to lyse targets was not due to diminished cell numbers, as
a comparable increase in the total number of Kd/SYNTGRFPPL- and Kd/
GFNKLRSTL-speciﬁc CD8 T cells was observed after rechallenge with
Vac-DG or Vac-M2, respectively (Fig. 4D). These data, in combination
with the cytokine production data in Fig. 4B, indicate that on a per-cell

basis, compared to the memory response of both Kd/GFNKLRSTL- and
K d /KYGRLFNEI-speciﬁc memory CD8 T cells, long-lived K d /
SYNTGRFPPL-speciﬁc CD8 T cells have a memory response of much
lower quality. Although long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T cells
are maintained in response to antigen, they very poorly produce effector
cytokines or lyse peptide-pulsed target cells after restimulation with a
vaccinia vector.
Long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T cells are unable to confer
protection in CD8−/− recipient mice upon challenge with
LP-BM5 retrovirus
Since long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T cells had a
memory response of poor quality, we reasoned that these long-lived
CD8 T cells might be unable to confer protection in CD8−/− mice
during infection with LP-BM5 retrovirus, despite the fact that Kd/
SYNTGRFPPL-speciﬁc CD8 T cells were protective as acute effectors. To
test this hypothesis, we utilized two different approaches: (1) direct
LP-BM5 infection of naive (not initially infected) CD8−/− recipient
mice previously administered acute effector Kd/SYNTGRFPPL-speciﬁc
CD8 T cells 11 weeks prior and (2) recovery of long-lived Kd/
SYNTGRFPPL-speciﬁc CD8 T cells either from LP-BM5-infected
primary CD8−/− recipient mice that were protected during initial
LP-BM5 infection (antigen-experienced Kd/SYNTGRFPPL-speciﬁc CD8
T cells) or from non-infected (antigen-independent Kd/SYNTGRFPPLspeciﬁc CD8 T cells) primary CD8−/− recipient mice given acute Kd/
SYNTGRFPPL-speciﬁc CD8 T cells 11 weeks prior. In approach 2, longlived Kd/SYNTGRFPPL-speciﬁc CD8 T cells were recovered from these
primary CD8−/− recipient mice and transferred into secondary LPBM5-infected CD8−/− recipients. As we have previously published
(Ho and Green, 2006b), the transfer of acute Kd/SYNTGRFPPL-speciﬁc
effector CD8 T cells into primary CD8−/− recipient mice resulted in
signiﬁcant protection compared to LP-BM5-infected CD8−/− recipients that did not receive transfer of CD8 T cells, as evidenced by all
disease readouts and viral load (Supplementary Fig. 3A–D) and as
summarized by disease index (Fig. 5A).
Although acute Kd/SYNTGRFPPL-speciﬁc effector CD8 T cells were
able to protect against LP-BM5-mediated disease in the primary
CD8−/− recipients (Fig. 5A), long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T
cells isolated from primary CD8−/− recipients 11 weeks post-transfer
were unable to confer equivalent protection compared to the disease
index of non-infected control CD8−/− mice depicted in Fig. 5D,
regardless of whether they were antigen-independent and negatively
puriﬁed from non-infected primary CD8−/− recipients receiving acute
Kd/SYNTGRFPPL-speciﬁc effector CD8 T cells (Fig. 5B, left histogram,
and Supplementary Fig. 4) or experienced antigen and were
negatively puriﬁed from primary CD8−/− recipients previously
infected with LP-BM5 (Fig. 5C and Supplementary Fig. 4). Diminished
protection was not merely a result of the system of puriﬁcation and
transfer of long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T cells, as direct
infection of primary CD8−/− recipient mice given acute effector CTL
11 weeks prior also developed signiﬁcant disease (Fig. 5B, right
histogram, and Supplementary Fig. 4). These data indicate that, although
acute Kd/SYNTGRFPPL-speciﬁc effector CD8 T cells are able to confer
protection during LP-BM5 infection in primary CD8−/− recipients, their

Fig. 4. Compared to Kd/GFNKLRSTL-speciﬁc memory and recalled CD8 T cells, long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T cells have impaired functional memory/recall responses.
Effector CTLs, derived from either Vac-DG or Vac-M2 primed BALB/c mice, were either transferred into individual CD8−/− recipient mice or co-transferred into a recipient CD8−/−
mouse at a 1:1 ratio based upon tetramer staining. (A) Acute 5-day Vac-DG primed effector CD8 T cells recognizing SYNTGRFPPL or KYGRLFNEI have similar cytolytic capabilities
after transfer into CD8−/− recipients. In vivo cytolysis was measured by transferring LP-BM5-speciﬁc SYNTGRFPPL- and vaccinia-speciﬁc KYGRLFNEI-pulsed target splenocytes
labeled with different ratios of CFSE into CD8−/− recipients. (B) Intracellular staining of IFNγ and TNFα by long-lived Kd/SYNTGRFPPL- or Kd/GFNKLRSTL-speciﬁc CD8+ T cells
11 weeks post-transfer into individual CD8−/− recipients or into the same CD8−/− recipient at a 1:1 ratio. Numbers in quadrants represent percent mean ± standard deviation of
total CD8+ T cells staining positive for each cytokine. (C) In vivo cytolysis of SYNTGRFPPL-, KYGRLFNEI-, or GFNKLRSTL-pulsed target cells by long-lived memory (no boost) and VacDG boosted Kd/SYNTGRFPPL-, or Vac-M2 boosted Kd/GFNKLRSTL-, speciﬁc CD8 T cells 11 weeks post-transfer into individual CD8−/− recipients, or co-transferred into the same
recipient at a 1:1 ratio based upon tetramer staining. (D) Increased numbers of long-lived Kd/SYNTGRFPPL- or Kd/GFNKLRSTL-speciﬁc CD8+ T cells 5 days post-boosting with
vaccinia virus. Totals are calculated based upon %total CD8+ tetramer+ cells detected in boosted and non-boosted CD8−/− recipient mice by ﬂow cytometry. Data are representative
of at least 2 experiments with 4–6 animals per group. *P b 0.05; **P b 0.01.
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ability to recall to antigen as memory cells is severely impaired, resulting
in secondary CD8−/− recipients developing MAIDS, similar to that of
control LP-BM5-infected CD8−/− mice (Fig. 5D).
Discussion
In this study, we have shown that although acute K d /
SYNTGRFPPL-speciﬁc CD8 T cells acquired similar effector functional
abilities compared to canonical Kd/GFNKLRSTL-speciﬁc C62Llow
effector CD8 T cells, they maintained moderate/high surface levels
of CD62L expression (Fig. 2B, Supplementary Fig 2). Despite the
higher expression levels of CD62L, these acute effector CTLs were
indeed able to protect LP-BM5-susceptible CD8−/− mice during
infection with this retrovirus, as we have previously published (Ho
and Green, 2006b) (Fig. 5A and Supplementary Fig. 3A–D). However,
we found that, although long-lived memory Kd /SYNTGRFPPLspeciﬁc CD8 T cells were able to persist without the requirement
of antigen (Fig. 2A), they were fundamentally impaired in their
ability to mount cytokine responses or lyse antigen-pulsed target
cells during antigen-speciﬁc recall (Figs. 2B and 4B–C). Transfer of
long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T cells into CD8−/− recipients infected with LP-BM5 conﬁrmed the apparent lack of function
in the memory population, as LP-BM5-infected CD8 −/− mice
receiving these long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T cells
developed full-blown MAIDS (Fig. 5B–C and Supplementary
Fig. 4A–D).
Typically, stimulation of primed antigen-speciﬁc CD44high T cells
with cognate antigen in vitro results in the downregulation of CD62L
as the cells acquire effector function. Indeed, the majority of CD62Llow
Kd/GFNKLRSTL-speciﬁc acute effector T cells were able to co-produce
cytokines IFNγ and TNFα after 9 days of in vitro expansion (Fig. 3B).
However, unlike acute Kd/GFNKLRSTL-speciﬁc effector T cells, after
culture in identical conditions but with SYNTGRFPPL peptide, the
majority of IFNγ and TNFα co-producing SYNTGRFPPL-speciﬁc T cells
expressed moderate/high levels of CD62L (Supplemental Fig. 1C and
Fig. 3A). Recent reports have associated the cleavage of CD62L with
rapid and efﬁcient viral clearance (Richards et al., 2008), perhaps
suggesting a predisposing factor, if not a mechanism, of relevance to
our observation that long-lived CD62Lmoderate/high Kd/SYNTGRFPPLspeciﬁc CD8 T cells are poorly able to recall against antigen or protect
secondary CD8−/− recipients during LP-BM5 infection. The possibility exists that the IFNγ and TNFα co-producing acute effector
CD62Lmoderate/high population were unable to shed CD62L, in
comparison to acute CD62Llow effector CD8 T cells generated in
identical conditions against a conventional antigen (Kd/GFNKLRSTLspeciﬁc CD8 T cells).
However, recently, it has been reported that the generation of
protective functional memory T cells occurs irrespective of CD62L
expression and is more dependent upon the anatomical location of
memory T cells during secondary encounter with antigen
(Kedzierska et al., 2007). Although acute Kd/SYNTGRFPPL-speciﬁc
effector CD8 T cells expressed moderate/high levels of CD62L, they
were still capable of cytolysis and effector cytokine production during
stimulation with peptide in vitro. The inability of long-lived Kd/
SYNTGRFPPL-speciﬁc CD8 T cells to protect CD8−/− recipient mice
may not be simply due to CD62L expression, as acute and long-lived
Kd/SYNTGRFPPL-speciﬁc CD8 T cells had similar expression levels of
CD62L, compared to naive cells (Supplementary Fig. 2). Although the
moderate/high CD62L expression on acute effectors may be predictive of a memory response of poor quality, CD62L expression alone
may thus not be directly linked to the impaired nature of the
memory CD8 T cell response against SYNTGRFPPL. With regard to the
generation of highly functional memory CD8 T cell responses using
vaccinia-based expression vectors, the results presented here are
interesting to consider in light of the recent publication by Yewdell
(2010). It was shown that inﬂammatory vectors such as vaccinia

provide far greater amounts of vector antigen for resident APCs,
outcompeting the numbers of CD8 T cells primed against weaker or
less abundant antigens (Yewdell, 2010). In terms of our model, the
possibility remains that the memory response to SYNTGRFPPL could
be rescued by using a less inﬂammatory vector during recall.
The cardinal feature of memory CD8 T cells is the ability to rapidly
recall against antigen in a qualitatively and quantitatively greater
capacity than the acute effector CD8 T cell response. Several studies
have implicated that the qualitative functions of the CD8 T cell
response, not the magnitude, inﬂuence the clinical outcome during
progression to AIDS (Almeida et al., 2007; Critchﬁeld et al., 2008;
Ferre et al., 2009). In relation to targeting CTL responses against
cryptic epitopes in HIV, the data obtained suggest that, at least in our
system, although a cryptic antigen elicits a protective acute CD8 T
cell response, there exists the potential that there may be a decrease
in the qualitative effector functions of memory CD8 T cells during
recall. In an analogous fashion, perhaps CTL responses against certain
highly conserved HIV-encoded cryptic or conventional epitopes may
evolve into functionless memory cells. Indeed, we have previously
shown that acute SYNTGRFPPL-speciﬁc CTL secrete effector cytokines
and induce perforin-mediated lysis of target cells (Ho and Green,
2006b; Rutkowski et al., 2009), resulting in protection of susceptible
mice. However, long-lived SYNTGRFPPL-speciﬁc CD8 T cells were
unable to lyse target cells and confer protection during infection with
LP-BM5 (Figs. 4C and 5). Our system presents an opportunity to
examine in detail possible therapeutic strategies designed at
boosting the memory CD8 T cell response against the cryptic epitope
SYNTGRFPPL. With respect to therapeutic vaccine strategies, these
studies suggest a basis for the rational design and analysis of
protective vaccines that elicit polyfunctional and long-lasting
protective CD8 T cell responses.
The ability of CD8 T cells to respond effectively against HIVassociated antigens during infection is impaired partially due to the
emergence of HIV-1 quasispecies lacking peptide sequences previously recognized by protective CD8 T cells, ultimately resulting in
diminished control of the virus set point and progression to AIDS.
Reversion to the immunodominant epitopes after transmission to
MHC-disparate hosts in humans (Friedrich et al., 2004; Leslie et al.,
2004), and replicative deﬁciencies of escaped mutants during
challenge of macaques with SIV compared to wild-type strains
(Friedrich et al., 2004) suggest that virus escape from immune
pressure exacts a ﬁtness cost to the virus. Nonetheless, virus escape
from immune pressure has impeded the success of therapeutic
measures targeted at boosting the endogenous CD8 T cell-mediated
response to control viral levels. However, recent studies have
demonstrated the presence of highly conserved immunodominant
cryptic epitopes located within alternate reading frames of the viral
genome (Bansal et al., 2010; Cardinaud et al., 2004; Maness et al.,
2007). Although immune pressure against cryptic epitopes may also
be signiﬁcant, genetic constraints may exist, resulting in a relatively
broad array of highly conserved immunodominant cryptic epitopes
(Cardinaud et al., 2004; Ho and Green, 2006a; Mayrand and Green,
1998). Collectively, these studies highlight the previously underappreciated potential of using cryptic epitopes in HIV-1 vaccines and
underscore the importance of fully characterizing the recall response
against cryptic antigens using the model employed here to directly
test protection after priming and boosting with relevant cryptic
epitope-based vaccines.
Materials and methods
Mice
Female BALB/c w.t. mice (6–8 weeks old) were purchased from the
National Cancer Institute (NCI, Bethesda, MD). Breeding pairs of
CD8−/− knockout mice on the BALB/c background were kindly
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Fig. 5. Unlike acute effector Kd/SYNTGRFPPL-speciﬁc CD8 T cells, long-lived Kd/SYNTGRFPPL-speciﬁc CD8 T cells are unable to protect susceptible CD8−/− recipient mice during LPBM5 disease. (A) Extent of disease following infection of primary CD8−/− recipient mice. Primary CD8−/− recipient mice were either infected or non-infected with LP-BM5 retrovirus
and administered acute Kd/SYNTGRFPPL-speciﬁc effector CD8 T cells (ORF2/SYN CD8+) 11 weeks prior. ***P b 0.001 compared to CD8−/− mice infected with LP-BM5 only (second
bar from the left). (A–B) CD8 T cells were isolated from either non-infected or LP-BM5-infected mice that received acute ORF2/SYN CD8+ 11 weeks prior, as indicated by arrow.
(B) Secondary transfer of antigen-independent long-lived ORF2/SYN CD8+ to CD8−/− mice infected with LP-BM5 retrovirus (left histogram). Alternatively, a group of non-infected
primary CD8−/− recipients that received ORF2/SYN CD8+ T cells 11 weeks prior were directly infected with LP-BM5 retrovirus (direct inf.) (right histogram). (C) Secondary transfer
of antigen-experienced long-lived ORF2/SYN CD8+ to CD8−/− mice infected with LP-BM5 retrovirus. (D) Parallel disease of naive CD8−/− control mice infected at the same time as
the infection of the secondary recipients. The disease index of CD8−/− mice either infected or non-infected with LP-BM5 retrovirus that did not receive donor acute effector or longlived ORF2/SYN CD8+ T cells. ***P b 0.001 compared to non-infected CD8−/− mice that did not receive donor cells in panel D.

provided by P. Stuart (Washington University, St. Louis, MO) and T.
Mak (Ontario Cancer Institute, Toronto, Canada). Mice were bred and
housed in speciﬁc pathogen-free conditions in the Dartmouth Medical
School Animal Resource Center. All experimental procedures were
approved by and performed under the requirements set forth by the
AAALAC accredited Animal Care and Use Program of Dartmouth
College.
Cell lines, viruses, and reagents
The P815B mouse mastocytoma cell line (H-2d), provided by J.
Bennink (NIH/NIAID, Bethesda, MD), was maintained in RPMI 1640

supplemented with 5% fetal calf serum, 2 mM L-glutamine, 30 μg/ml
penicillin, 20 μg/ml streptomycin, and 33 μg/ml gentamicin. The
murine retrovirus LP-BM5, originally provided by J. W. Hartley and
H. C. Morse (National Institutes of Health/National Institute of Allergy
and Infectious Diseases, Bethesda, MD), was propagated in our
laboratory as previously described (Green et al., 2008; Klinken et al.,
1988). Vac-DG, the recombinant vaccinia virus with the gag gene of
the LP-BM5 retrovirus inserted, was generated as previously described (Schwarz and Green, 1994). Vac-M2, the recombinant
vaccinia virus with the gammaherpesvirus latent gene inserted,
generated by A. McCrae and J. Stewart (University of Liverpool, UK),
was a generous gift from E. Usherwood (Dartmouth College). The LP-
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BM5 ORF2 peptide (SYNTGRFPPL) was purchased from Invitrogen
(Carlsbad, CA) at N95% purity. The H-2Kd-restricted gammaherpesvirus latent peptide M291–99 (GFNKLRSTL) and H-2Kd-restricted
vaccinia-speciﬁc peptide (KYGRLFNEI) were purchased from New
England Peptides (Gardner, MA) at 95% purity. Tetramer, consisting of
Kd folded with SYNTGRFPPL peptide and labeled with allophycocyanin, was provided by the NIH Tetramer Core Facility (Atlanta, GA). The
allophycocyanin-labeled tetramer, consisting of Kd folded with
GFNKLRSTL, was a generous gift from E. Usherwood.
Infection, rechallenge, and adoptive transfer experiments
For all LP-BM5 infections, mice were infected intraperitoneally (i.p.)
with the indicated amounts of LP-BM5 retrovirus. For rechallenge
experiments, immune or naive mice were injected i.p. with 3 × 105 pfu of
Vac-DG 5 days prior to harvesting splenocytes for immunological
readouts or in vivo cytotoxicity assays. For experiments using acute
effector Kd/SYNTGRFPPL-speciﬁc CD8 T cells, antigen-speciﬁc T cells
were enriched by depletion of CD19+ cells using magnetic beads
(Miltenyi, Auburn CA) from BALB/c mice primed 1 week prior with
3 × 107 pfu Vac-DG and approximately 1–2 × 107 splenocytes/recipient
were transferred into CD8−/− recipient mice. For the generation of longlived Kd/SYNTGRFPPL-speciﬁc or Kd/GFNKLRSTL-speciﬁc CD8 T cells, w.t.
BALB/c mice were immunized with 3 × 107 pfu of Vac-DG or Vac-M2 as
previously reported (Ho and Green, 2006b). Approximately 3 weeks
post-priming, antigen-sensitized splenocytes were isolated from Vac-DG
or Vac-M2-primed mice followed by incubation with the 10 ng/ml of
SYNTGRFPPL or GFNKLRSTL peptide, respectively, for 6 days and an
additional 3 days of culture with 5U/ml of rIL-2 (Cetus Corporation,
Everyville, CA). Prior to adoptive transfer into BALB/c CD8−/− recipients,
CTLs were characterized for antigen speciﬁcity by staining with tetramer.
SYNTGRFPPL-speciﬁc cytotoxicity and effector cytokine production of
IFNγ, TNFα, and IL-2 were assessed by using the standard 51Cr release
assay (Schwarz and Green, 1994) and intracellular cytokine staining,
respectively. For four consecutive 3-day intervals, CTLs containing
approximately 5 × 105 ORF2/SYNTGRFPPL-speciﬁc CTL (enumerated by
tetramer staining) were transferred intravenously into naive or CD8−/−
recipients infected with LP-BM5 3 days prior.

capture antibody (BD Pharmingen) overnight at 4 °C. Plates were
washed and blocked with media containing 10% FBS for 2 h at 37 °C.
Splenocytes from immune and non-immune mice were plated at
5 × 105 cells/well in triplicate together with 106 irradiated (3000 rad)
syngeneic splenocytes and 10 μg/ml stimulating SYNTGRFPPL, or
irrelevant GFNKLRSTL, peptide and 10 U/ml rIL-2 for 48 h at 37 °C.
After 48 h, plates were washed with PBS containing 0.5% Tween-20
(0.5% PBS) followed by incubation with 2 μg/ml biotinylated rat antimouse IFNγ detecting mAb at 4 °C for a minimum of 2 h. Plates were
washed and spots were visualized by the addition of streptavidin–
alkaline phosphatase for 1 h at room temperature followed by
washing and addition of 5-bromo-4-chloro-3-indolyl phosphate/
nitroblue tratazolium (BCIP/NBT substrate; Sigma) for 30–60 min at
room temperature.
Tetramer staining
ORF2/SYNTGRFPPL-speciﬁc CTLs were incubated with anti-FcγII/III
on ice for 10 min. Cells were then incubated with APC-conjugated Kd/
SYNTGRFPPL tetramer or control APC-conjugated Kd/GFNKLRSTL at
room temperature for 1 h, followed by labeling with PercP-anti-CD8α,
and either PE-anti-CD127, or PE-anti-CD44, or PE-anti-CD122; and
FITC-anti-CD43 (1B11 clone) or FITC-anti-CD62L for 20 min on ice.
Stained cells were then washed thoroughly and analyzed on a
FACSCalibur as previously stated.
In vivo cytotoxicity assay

In vitro cytolytic activity was determined using a standard 51Cr
release assay with P815B target cells pulsed with 200 μCi of 51Cr,
followed by pulsing with or without 100 ng/ml of either SYNTGRFPPL,
GFNKLRSTL, or KYGRLFNEI synthetic peptides at 37 °C for 30 min in
RPMI supplemented with 10% calf serum, 30 μg/ml penicillin, and
20 μg/ml streptomycin. Target cells were ad-mixed at the indicated
ratios with effector CD8 T cell populations and incubated at 37 °C for
6 h. Percent speciﬁc lysis was calculated as previously described
(Schwarz and Green, 1994).

In vivo measurement of antigen-speciﬁc CD8 cytolytic activity was
performed as previously described (Barber et al., 2003; Fuse and
Usherwood, 2007). Brieﬂy, syngeneic BALB/c splenocytes were pulsed
with 2 μg/ml of the indicated peptides, or no peptide, for 1 h at 37 °C
in serum-free media. Cells were washed and labeled with the
following cellular dyes: 2 μM or 0.2 μM carboxyﬂuorscein succinimidyl ester (CFSE; Invitrogen, Eugene, OR) in serum free media for
10 min at room temperature, or 10 μM Cell Tracker Orange,
chloromethyl-benzoyl-aminotetramethyl-rhodamine (CMTMR; Invitrogen) for 30 min in media with 10% serum at 37 °C, followed by an
additional 30-min incubation at 37 °C in media with 10% serum
without the cellular dye. After the incubation periods, cells were
washed extensively, counted, and combined at a 1:1:1 ratio, with an
approximate total of 0.8–2 × 107 cells injected intravenously into
recipient mice. Sixteen hours post-transfer, mice were sacriﬁced and
spleen cell suspensions were collected, counted, and incubated with
25 μg/ml of 7-amino-actinomycin D (7-AAD; BD Pharmingen) at room
temperature for 10 min to exclude all non-viable splenocytes. Speciﬁc
lysis was calculated using the following formulas: ratio = (number of
peptide labeled targets/number of non-labeled targets); percentage of
speciﬁc lysis = (1 − (ratio immunized/ratio naive) × 100).

Intracellular cytokine staining

LP-BM5 disease measurement

Intracellular staining for cytokines IFNγ, TNFα, and IL-2 was
performed as previously described (Rutkowski et al., 2009). Cells
were cytoplasmically stained with APC-conjugated-anti-mouse
IFNγ, PE-conjugated anti-mouse TNFα, or FITC-conjugated antimouse IL-2, or the appropriate isotype control mAbs. All antibodies
were from either BD Biosciences (San Jose, CA) or eBioscience (San
Diego, CA).

For analysis of LP-BM5-induced activational disease parameters,
lymphoproliferation was determined by measuring spleen weight,
and hypergammaglobulinemia was assessed via measuring serum
levels of IgG2A and IgM in a standard ELISA assay, as previously
described in detail (Green et al., 2008; Li and Green, 2006), from
serum previously separated from peripheral blood of sacriﬁced mice.
Immunodeﬁciency was measured using ConA and LPS mitogeninduced proliferation assays of isolated splenocytes as previously
described (Green et al., 2008; Li and Green, 2006). For calculation of
viral load, mRNA encoding the BM5 defective (BM5def) and
ecotropic (BM5eco) gag genes was ampliﬁed from puriﬁed splenic
RNA by separate real-time RT-PCR assays as previously described
(Cook et al., 2003).

Chromium release cytotoxicity assays

IFNγ enzyme-linked immunospot assay (ELISPOT)
Lymphocytes secreting IFNγ were quantiﬁed using a standard
ELISPOT assay. Flat-bottomed 96-well HTS nitrocellulose plates
(Millipore, Bedford, MA) were coated with rat anti-mouse IFNγ
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Calculation of disease index
Disease index was calculated as previously described (Rutkowski
et al., 2009). Brieﬂy, percent disease of all experimental mice for each
disease parameter (splenomegaly, LPS and ConA mitogen response,
and serum levels of IgG2A and IgM) was calculated using the formula:
((experimental value − mean value of non-infected controls)/(mean
value of LP-BM5-infected controls − mean value of non-infected
controls)) × 100. Mice with 0% or calculated “negative” disease for
any one parameter were assigned a value of 0, mice with 1–20% disease
were assigned a value of 0.5, mice with 21–40% disease were assigned
a value of 1, mice with 41–60% disease were assigned a value of 2, mice
with 61–80% disease were assigned a value of 3, mice with 81–100%
disease were assigned a value of 4, and mice with greater than 100%
disease were assigned a value of 5. Values for all parameters were
combined for each experimental set of mice and graphed.
Statistics
Prism (GraphPad; San Diego, CA) was used for all statistical tests of
signiﬁcance (P values of ≤ 0.05).
Supplementary materials related to this article can be found online
at doi:10.1016/j.virol.2010.11.013.
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